Transgene Statistics

Total Valuation

Transgene has a market cap or net worth of EUR 81.54 million. The enterprise value is 75.26 million.

Market Cap	81.54M
Enterprise Value	75.26M

Important Dates

The next estimated earnings date is Tuesday, September 16, 2025.

Earnings Date	Sep 16, 2025
Ex-Dividend Date	n/a

Share Statistics

Transgene has 131.93 million shares outstanding. The number of shares has increased by 15.98% in one year.

Current Share Class	n/a
Shares Outstanding	131.93M
Shares Change (YoY)	+15.98%
Shares Change (QoQ)	+31.12%
Owned by Insiders (%)	70.07%
Owned by Institutions (%)	1.00%
Float	34.66M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	12.83
PB Ratio	5.36
P/TBV Ratio	5.38
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-2.22
EV / Sales	11.85
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-2.83

Financial Position

The company has a current ratio of 1.48, with a Debt / Equity ratio of 0.68.

Current Ratio	1.48
Quick Ratio	1.39
Debt / Equity	0.68
Debt / EBITDA	n/a
Debt / FCF	-0.39
Interest Coverage	-21.21

Financial Efficiency

Return on equity (ROE) is -220.48% and return on invested capital (ROIC) is -76.18%.

Return on Equity (ROE)	-220.48%
Return on Assets (ROA)	-51.00%
Return on Invested Capital (ROIC)	-76.18%
Return on Capital Employed (ROCE)	-126.48%
Revenue Per Employee	44,118
Profits Per Employee	-235,910
Employee Count	144
Asset Turnover	0.15
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -54.22% in the last 52 weeks. The beta is 0.89, so Transgene's price volatility has been lower than the market average.

Beta (5Y)	0.89
52-Week Price Change	-54.22%
50-Day Moving Average	0.67
200-Day Moving Average	0.85
Relative Strength Index (RSI)	43.77
Average Volume (20 Days)	30,605

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Transgene had revenue of EUR 6.35 million and -33.97 million in losses. Loss per share was -0.29.

Revenue	6.35M
Gross Profit	-27.93M
Operating Income	-35.66M
Pretax Income	-33.97M
Net Income	-33.97M
EBITDA	-34.37M
EBIT	-35.66M
Loss Per Share	-0.29

Full Income Statement

Balance Sheet

The company has 16.67 million in cash and 10.40 million in debt, giving a net cash position of 6.27 million or 0.05 per share.

Cash & Cash Equivalents	16.67M
Total Debt	10.40M
Net Cash	6.27M
Net Cash Per Share	0.05
Equity (Book Value)	15.20M
Book Value Per Share	0.12
Working Capital	6.68M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -23.55 million and capital expenditures -3.07 million, giving a free cash flow of -26.61 million.

Operating Cash Flow	-23.55M
Capital Expenditures	-3.07M
Free Cash Flow	-26.61M
FCF Per Share	-0.20

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-561.23%
Pretax Margin	-534.72%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Transgene does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-15.98%
Shareholder Yield	-15.98%
Earnings Yield	-41.66%
FCF Yield	-32.64%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Transgene has an Altman Z-Score of -4.37. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-4.37
Piotroski F-Score	n/a